Navigation Links
Pitt team identifies key protein causing excess liver production of glucose in diabetes
Date:9/28/2011

PITTSBURGH, Sept. 28 Researchers at the John G. Rangos Sr. Research Center at Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine have identified a powerful molecular pathway that regulates the liver's management of insulin and new glucose production, which could lead to new therapies for diabetes. The findings were published online this week in Diabetes, a journal of the American Diabetes Association.

Usually, the liver stores excess blood sugar as glycogen, which it doles out overnight during sleep and other periods of fasting to keep glucose levels within a normal physiological range, explained H. Henry Dong, Ph.D., associate professor of pediatrics, Pitt School of Medicine. But in diabetes, the liver continues to pump out glucose even when insulin is provided as a treatment.

"Scientists have been trying to find the factors that contribute to this liver overproduction of glucose for decades," Dr. Dong said. "If we can control that pathway, we should be able to help reduce the abnormally high blood sugar levels seen in patients with diabetes."

He and his team have been studying a family of proteins called Forkhead box or FOX, and for the current project focused on one called FOX06. They found that mice engineered to make too much FOX06 developed signs of metabolic syndrome, the precursor to diabetes, including high blood sugar and high insulin levels during fasting as well as impaired glucose tolerance, while mice that made too little FOX06 had abnormally low blood sugars during fasting.

"In a normal animal, a glucose injection causes blood sugar level to rise initially and then it goes back to normal range within two hours," Dr. Dong said. "In animals that made too much FOX06, blood sugar after a glucose injection doesn't normalize within two hours. They have lost the ability to regulate the level while the liver keeps making unneeded glucose."

Other experiments showed that diabetic mice have abnormally high levels of FOX06 in the liver, he added. Blocking the protein markedly reduced liver production of glucose, although blood sugar did not completely normalize. Within two weeks of treatment, there was significant improvement in blood sugar and glucose metabolism in diabetic mice.

Tests with human liver cells echoed the importance of FOX06's role in glucose production.

"These findings strongly suggest that FOX06 has potential to be developed as a therapeutic target," Dr. Dong said. "If we can inhibit its activity, we can possibly slow the liver's production of glucose in patients with diabetes and better control blood sugar levels."


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. International study identifies new gene targets for hypertension treatment
2. UT Southwestern program identifies families at high risk for colorectal cancer
3. Worldwide map identifies important coral reefs exposed to stress
4. Watermark ink device identifies unknown liquids instantly
5. Research identifies genes vital to preventing childhood leukemia
6. Scleroderma study identifies roadblocks to employment
7. Team identifies new breast cancer tumor suppressor and how it works
8. BUSM study identifies new potential approaches to treat myelofibrosis
9. Research identifies how cancer cells cheat death
10. TGen study identifies compounds that could slow down Alzheimers disease
11. AMIA identifies areas to strengthen Federal health IT strategic plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):
(Date:8/10/2017)... ... August 09, 2017 , ... ... in the clinic is here. The team at Capricor Therapeutics, Inc. utilized a ... for clinical studies. , Dr. Travis Antes, head of analytical development at ...
(Date:8/10/2017)... SAN DIEGO, California, USA (PRWEB) , ... August ... ... and photonics, has partnered with four international biomedical optics laboratories — the Wellman ... Massachusetts General Hospital, Medical Laser Center Lübeck and the Beckman Laser Institute at ...
(Date:8/10/2017)... Coral Springs, FL (PRWEB) , ... August 10, ... ... today announced that the stock market news outlet had initiated coverage on Next ... the rapidly growing and underserved consumer markets geared toward those that cannot engage ...
(Date:8/8/2017)... ... August 08, 2017 , ... HumanZyme Inc., a leading ... today announced the launch of HumanKine® Interferon beta (IFN beta) expressed ... interferons that activate Th1-type innate immune responses against viral and bacterial infection, and have ...
Breaking Biology Technology: